ArticleFrontiers in public health2026
Genomic characterization of selected influenza A-positive specimens and an A(H1N1)pdm09/SARS-CoV-2 co-infection in the Republic of Moldova.
Article in Frontiers in public health, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Genomic sequencing can complement routine influenza surveillance by enabling clade-level characterization of selected specimens and the genomic characterization of mixed viral specimens. This descriptive laboratory-based study characterized influenza A-positive respiratory specimens collected through routine surveillance in the Republic of Moldova and selected for sequencing. Methods: Between October 2025 and February 2026, 1,081 respiratory specimens were screened by multiplex real-time reverse transcription polymerase chain reaction for influenza A, influenza B, and SARS-CoV-2. Of 291 influenza A-positive specimens, 174 had cycle-threshold values ≤27, and 38 were selected for hybrid-capture sequencing based on repeat cycle-threshold values and technical suitability. Consensus sequences were analyzed with Nextclade, and the SARS-CoV-2 component of one mixed specimen was additionally assessed using Pangolin. Results: All 38 selected specimens yielded analyzable influenza A hemagglutinin sequences, with hemagglutinin-segment coverage ranging from 87.6% to 100%. The dataset comprised 32 A(H3N2) specimens, five A(H1N1)pdm09 specimens, and one mixed A(H1N1)pdm09/SARS-CoV-2 specimen. All A(H3N2) hemagglutinin sequences were assigned to clade K, subclade 2a.3a.1. The six A(H1N1)pdm09 hemagglutinin components were assigned to clade D.3.1 ( Conclusion: The study provides a descriptive genomic characterization of a laboratory-selected subset and illustrates a workflow linking molecular testing to sequencing. The findings should not be interpreted as estimates of national clade prevalence, geographical distribution, or A(H1N1)pdm09/SARS-CoV-2 co-infection frequency.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.